Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

February 12, 2009 updated by: University Hospital, Saarland

Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction

The purpose of the study is to determine the effect of fluvastatin on penile arterial blood flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Physiology of erection is mainly dependent on endothelial NO-production with consecutive activation of guanylate-cyclase. Pleiotropic effects of statins are well known regarding the increase of endothelial function. Thus, activation of endothelial NO-synthase could raise the activation of guanylate-cyclase with a consecutive relaxation of smooth muscle cells in the penile arteries and the corpus cavernosum leading to an improvement of erectile function. Therefore, statins are supposed to be effective in the treatment of erectile dysfunction, especially in patients with cardiovascular risk-factors with underlying endothelial dysfunction.

The effect of fluvastatin on penile blood-flow and erectile function in patients with arteriogenic erectile dysfunction and cardiovascular risk factors will be determined in a cross-over design. Patients were either treated with fluvastatin-sodium 80mg or placebo for 8 weeks. After a wash-out of 4 weeks, treatment will be switched (placebo / fluvastatin-sodium). Penile blood flow measurement and assessment of erectile function with the IIEF-5-score and the KEED-score will be performed at baseline, after 8 weeks of treatment, after 4 weeks wash-out and after cross-over treatment (8 weeks).

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Saarland
      • Homburg, Saarland, Germany, 66421
        • University Hospital of the Saarland

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • male
  • age > 18 years
  • arteriogenic erectile dysfunction (penile blood flow - peak systolic velocity<30cm/s, diastolic velocity<5cm/s)
  • two or more cardiovascular risk factors (smoking, hypertension, hyperlipoproteinaemia, family history of atherosclerosis, oral treated diabetes mellitus with a HbA1c<7%)
  • stable course of disease without expected changes in medical treatment during the next 3 months
  • written informed consent
  • no statin-treatment so far

Exclusion Criteria:

  • known hypersensitivity or anaphylaxis against a statin
  • active liver disease or unclear increase of transaminases, cholestasis or myopathy
  • acute cardiovascular event (myocardial infarction, stroke, PTCA, vascular surgery) within 3 months before randomization
  • clinical signs of heart failure or reduced left ventricular function
  • current treatment with lipid lowering drugs
  • insulin dependent diabetes mellitus or orally treated diabetes mellitus with a HbA1c-value >6.9%
  • erectile dysfunction due to hormone disorders
  • known malignant tumor
  • known disposition to priapism
  • patients with morphological changes of the penis (i.e. deviation) or penis-prosthesis
  • current treatment with anticoagulants
  • current treatment with immunosuppressive drugs, phenytoin, erythromycin, gemfibrozil or nicotinic acid derivates
  • absence or inability of written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Penile blood flow (peak systolic velocity, resistance index, pulsatility index) after 8 weeks of treatment.

Secondary Outcome Measures

Outcome Measure
Erectile function assessed with the IIEF-5 score (international index of erectile function) after 8 weeks of treatment.
Erectile function assessed with the KEED score (cologne questionnaire of erectile function) after 8 weeks of treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Magnus Baumhäkel, MD, University Hospital of the Saarland
  • Principal Investigator: Michael Böhm, MD, University Hospital of the Saarland
  • Principal Investigator: Martin Gerber, MD, University Hospital of the Saarland
  • Principal Investigator: Michael Stöckle, MD, University Hospital of the Saarland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2006

Study Completion (ANTICIPATED)

December 1, 2007

Study Registration Dates

First Submitted

September 27, 2006

First Submitted That Met QC Criteria

September 27, 2006

First Posted (ESTIMATE)

September 28, 2006

Study Record Updates

Last Update Posted (ESTIMATE)

February 13, 2009

Last Update Submitted That Met QC Criteria

February 12, 2009

Last Verified

February 1, 2009

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe